Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05DBY
|
|||
| Former ID |
DIB002648
|
|||
| Drug Name |
Imagabalin
|
|||
| Synonyms |
Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Generalized anxiety disorder [ICD-11: 6B00; ICD-10: F41.1] | Phase 3 | [1] | |
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H19NO2
|
|||
| Canonical SMILES |
CCCC(C)CC(CC(=O)O)N
|
|||
| InChI |
1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
|
|||
| InChIKey |
JXEHXYFSIOYTAH-SFYZADRCSA-N
|
|||
| CAS Number |
CAS 610300-07-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Agonist | [1], [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Oxytocin signaling pathway | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
| WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. | |||
| REF 2 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.